Chief Executive Officer, Enesi Pharma
David Hipkiss is the CEO of Enesi Pharma, a company developing next-generation unit solid dose injectable vaccination products enabled by its ImplaVax® technologies targeting multiple infectious diseases and emergent threat pathogens in both human and animal health.
Prior to co-founding Enesi in 2017, he was Chief Business Officer of Circassia Pharmaceuticals, and a member of its Senior Management Team with global group responsibility for all M&A, partnering and licensing activities. Before joining Circassia, David was CEO and co-founder of Prosonix, a particle engineering-enabled respiratory product company, taking it from its establishment in 2006, raising more than £25 million from leading international life sciences investors and institutions over several financing rounds, through to its successful sale to Circassia in 2015 for £100 million.
David has more than 25 years of business development and licensing experience concerning cutting-edge technologies in high growth, complex, IP-rich environments, with a prime focus on the pharmaceutical industry. He has also held a number of positions with increasing seniority at Air Products, Chiroscience /ChiroTech Technology Ltd, Ascot plc, Dow Pharma, and Accentus.
David holds a degree in Chemical Engineering from the University of Birmingham, UK